BioSpace News Archive

Glucose monitoring is a necessary step towards managing diabetes.

According to the report, the global testosterone replacement therapy market was valued at US$ 1,613.7 Mn in 2018 and is anticipated to expand at a CAGR of 4.4% from 2019 to 2027.

NANO-X IMAGING LTD (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the pricing of its initial public offering of 9,178,744 ordinary shares at a price to the public of US$18 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, are expected to be US$165.2 million. In addition, Nano

Acquisition will expand Cryoport’s presence in both the EMEA and APAC regions and broaden Cryoport’s range of temperature-controlled supply chain solutions for the life sciences; Upon closing, the acquisition is expected to be immediately accretive to earnings. [21-August-2020] NASHVILLE, Tenn. , Aug. 21, 2020 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”

This Display Case will be Allocated to Select, High Volume, Retail Locations in Support of Upcoming National Roll-out of Tauri-Gum™ Brand NEW YORK, NY, Aug. 21, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of functional “supplement” chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ong

Enteral nutrition or enteral feeding is defined as delivery of proteins, minerals, and other essential nutritional products directly into the stomach of a patient with the help of tubes.

The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026.

Alkermes plc announced that a joint meeting of the U.S. Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to review the New Drug Application for ALKS 3831 has been tentatively scheduled for Oct. 9, 2020.

The report suggests that rising demand for innovative technologies and adoption of rapid testing methods such as point of care testing is spurring the growth of meningitis diagnostic testing in coming years (2017 to 2025).

Revised Commercial Labeling Broadens Patient Population Who May be Candidates for Transcatheter Aortic Valve Replacement